1. Show article details.

    Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

    Benzinga – 3:52 AM ET 08/10/2022

  2. Show article details.

    Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

    Benzinga – 3:26 PM ET 08/09/2022

    Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

  3. Show article details.

    Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

    Benzinga – 1:26 PM ET 08/09/2022

    Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

  4. Show article details.

    Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket

    Benzinga – 5:49 AM ET 08/09/2022

      Don't forget to check out our premarket coverage here .

  5. Show article details.

    Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday

    Benzinga – 3:05 AM ET 08/08/2022

    Gainers  

  6. Show article details.

    BRIEF-Bluebird Bio Reports Second Quarter 2022 Financial Results And Highlights Operational Progress

    Reuters – 5:45 PM ET 08/04/2022

    bluebird bio Inc: * BLUEBIRD BIO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS. * BETI-CEL FOR BETA-THALASSEMIA PDUFA GOAL DATE IS SET FOR AUGUST 19, 2022. * ELI-CEL FOR CEREBRAL ADRENOLEUKODYSTROPHY PDUFA GOAL DATE IS SET FOR SEPTEMBER 16, 2022.

  7. Show article details.

    bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress

    Business Wire – 4:05 PM ET 08/04/2022

    - - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass---- bluebird bio, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.

  8. Show article details.

    Expert Ratings for bluebird bio

    Benzinga – 11:29 AM ET 08/02/2022

    Over the past 3 months, 4 analysts have published their opinion on bluebird bio stock. These 4 analysts have an average price target of $4.0 versus the current price of bluebird bio at $4.0481, implying downside. Below is a summary of how these 4 analysts rated bluebird bio over the past 3 months. This current average has not changed from the previous average price target.

  9. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

    Benzinga – 10:20 AM ET 08/02/2022

    For Transocean Ltd, Capital One upgraded the previous rating of Equal-Weight to Overweight. Raymond James upgraded the previous rating for Tricon Residential Inc from Outperform to Strong Buy. Credit Suisse upgraded the previous rating for BanColombia SA from Neutral to Outperform. Raymond James upgraded the previous rating for bluebird bio Inc from Market Perform to Outperform.

  10. Show article details.

    Biotech Investors: August's Key PDUFA Catalysts You Must Know

    Benzinga – 9:21 AM ET 07/31/2022

    Regulatory decisions have yet to pick up pace this year. The following treatments received Food and Drug Administration's blessings in July: Horizon Therapeutics Ltd.'s gout treatment Krystexxa got an expanded label to be used in combination with methotrexate.

  11. Show article details.

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    Benzinga – 8:14 AM ET 07/15/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  12. Show article details.

    Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday

    Benzinga – 5:21 AM ET 07/06/2022

  13. Show article details.

    Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session

    Benzinga – 12:05 PM ET 07/05/2022

    Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session

  14. Show article details.

    12 Health Care Stocks Moving In Thursday's Intraday Session

    Benzinga – 3:02 PM ET 06/23/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  15. Show article details.

    44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More

    Benzinga – 12:29 PM ET 06/23/2022

     Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.    Losers BIT Mining Limited shares dipped 40.4% to $0.7089 after the company announced a $16 million registered direct offering.  

  16. Show article details.

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    Benzinga – 5:42 PM ET 06/22/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

  17. Show article details.

    BRIEF-Bluebird Bio Inc - Entered Into Equity Distribution Agreement With Goldman Sachs & Co. Llc, As Our Sales Agent

    Reuters – 5:36 PM ET 06/22/2022

    BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - ENTERED INTO EQUITY DISTRIBUTION AGREEMENT WITH GOLDMAN SACHS & CO. LLC, AS OUR SALES AGENT. * BLUEBIRD BIO INC (BLUE) - MAY OFFER, SELL COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION FROM TIME TO TIME THROUGH OR TO THE SALES AGENT Source text for Eikon: [https://bit.ly/3zYqkDk] Further company coverage:

  18. Show article details.

    89 Biggest Movers From Friday

    Benzinga – 4:44 AM ET 06/21/2022

  19. Show article details.

    Dow Jones Turns Lower; Revlon Shares Jump

    Benzinga – 12:12 PM ET 06/17/2022

    U.S. stocks pared gains midway through trading, with the Dow Jones dropping around 100 points on Friday. The Dow traded down 0.35% to 29,821.15 while the NASDAQ rose 0.97% to 10,749.10. The S&P also fell, dropping, 0.16% to 3,660.85. Also check this: 3 Stocks Under $1 Insiders Are Buying Leading and Lagging Sectors Health care shares jumped by 0.4% on Friday.

  20. Show article details.

    33 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:12 PM ET 06/17/2022

     Gainers Revlon, Inc. gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.    Losers Renovare Environmental, Inc dipped 73.5% to $0.0450.

Page:

Today's and Upcoming Events

  • Nov
    03

    BLUE to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    BLUE announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.